CSI Market
Sign In | Register

Dar Bioscience Inc (DARE) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access DARE Annual Cash Flow →
This cash flow overview for Dar Bioscience Inc spans from Jun 30 2025 to Jun 30 2026, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-5.98
Depreciation & amortization1.13
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation1.44
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Straight Line Rent Adjustments-
Non Cash Lease Expense-
Increase Decrease In Deferred Grant Funding-1.50
Increase Decrease In Operating Lease Right Of Use Asset0.13
Non Cash Interest Expense On Liability Related To Sale Of Future Royalties-
Non Cash Royalty Revenue Related To Sale Of Future Royalties0.00
Increase Decrease In Operating Lease Liability-0.15
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable-0.12
Increase (Decrease) in Other Accounts Payable-0.44
Accrued Expense-0.09
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense1.38
Other Working Capital2.27
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-11.89
Discontinued operations0.00
Net Cash flow from Operating Activities-12.30
Investing Activities
Capital Expenditures-0.08
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Cash Acquired Through Reverse Merger-
Payments For Asset Acquisition-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Gross0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-1.34
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.08
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.03
Long-term debt - borrowings0.00
Long-term debt - repayments-0.18
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.26
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock1.53
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-1.34
Proceeds From Issuance Public Offering Net Of Issuance Costs-
Proceeds From Issuance Public Offering Net-
Payment End Term Charge On Loan Payable-
Net Proceeds From Issuance Of Common Stock And Warrants-
Proceeds From Issuance Of Common Stock And Warrants-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents25.01
Finance Lease Principal Payments-0.90
Repayment Of Liability On Sale Future Royalties-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.24
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-12.38
Total Cash Flow-12.09
4 historic quarters locked

Sign in to unlock the full Dar Bioscience Inc cash flow history.

Sign In Create Free Account

About Dare Bioscience Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001401914-26-000043

Figures are derived from filed reports and may be restated. Historical data is subject to revision.